Post by AKT Health Inc.

#RegulatoryAffairs and #MarketAccess get run as two different jobs, at two different times, by two different teams. That's not a staffing problem; it's the default way the industry has organized around this work for decades. We've sat on both sides of that split. - Regulatory strategy that gets a product approved, and access strategy that gets it reimbursed, funded, and actually prescribed. - What we keep seeing is the same evidence getting rebuilt twice, once for the regulator's questions, once for the payer's, because nothing carries it from one conversation to the other. That's the gap we've spent years working inside: #regulatorystrategy, #submissions, and quality & safety on one side; #clinicaldevelopment, market access, and #HEOR & evidence on the other. Not as separate service lines, but as one continuous strategy where decisions made early on how a study is designed, what evidence gets collected, and how it's documented are already built with the next conversation in mind. It's also why we're building one connected #regulatoryplatform behind the scenes, a system where regulatory, quality, safety, and access data live in one place instead of scattered across teams, so the evidence generated once doesn't have to be reconstructed for every audience that asks about it. Approval and access were never meant to be two separate finish lines. We're building toward the version where they don't have to be. Stay tuned for what's coming NEXT Where does this split cost your team the most time, rework, or missed context between functions? #LifeSciences #AKTHealth #RegTech #RIM #Regops #RegulatoryOperation